Pharming Group (PHGUF) Receives Consensus Recommendation of “Strong Buy” from Brokerages

Shares of Pharming Group (NASDAQ:PHGUF) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Zacks has also given Pharming Group an industry rank of 147 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised shares of Pharming Group from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research report on Saturday, November 5th.

Pharming Group (NASDAQ:PHGUF) remained flat at $0.33 during trading on Tuesday. The firm has a 50 day moving average price of $0.00 and a 200 day moving average price of $0.00. The firm’s market capitalization is $136.16 million. Pharming Group has a 1-year low of $0.17 and a 1-year high of $0.37.

“Pharming Group (PHGUF) Receives Consensus Recommendation of “Strong Buy” from Brokerages” was originally reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of US and international trademark & copyright laws. The original version of this piece of content can be viewed at

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

5 Day Chart for NASDAQ:PHGUF

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *